ChromaDex Corp. Files 8-K for Material Definitive Agreement
Ticker: NAGE · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1386570
| Field | Detail |
|---|---|
| Company | Chromadex Corp. (NAGE) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, sec-filing
TL;DR
CDXC signed a big deal, filing 8-K today. Watch this space.
AI Summary
On November 20, 2024, ChromaDex Corp. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Los Angeles, CA, filed this 8-K report with the SEC. This filing pertains to a significant contractual development for ChromaDex.
Why It Matters
This filing indicates a significant new contract or partnership for ChromaDex, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.
Key Numbers
- 001-37752 — SEC File Number (ChromaDex's SEC filing identifier)
- 26-2940963 — IRS Employer Identification No. (ChromaDex's tax identification number)
Key Players & Entities
- ChromaDex Corp. (company) — Registrant
- November 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Los Angeles, California (location) — Principal executive offices
- 10900 Wilshire Blvd. Suite 600 (address) — Principal executive offices address
FAQ
What is the nature of the material definitive agreement entered into by ChromaDex Corp. on November 20, 2024?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in this initial 8-K summary.
What is ChromaDex Corp.'s principal executive office location?
ChromaDex Corp.'s principal executive offices are located at 10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 20, 2024.
Under which act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is ChromaDex Corp.'s state of incorporation?
ChromaDex Corp. is incorporated in Delaware.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-11-21 16:01:28
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CDXC The Nasdaq Capital Mar
Filing Documents
- cdxc-20241120.htm (8-K) — 26KB
- atmamendmentno1november2.htm (EX-1.1) — 10KB
- atmamendmentno1november2001.jpg (GRAPHIC) — 203KB
- atmamendmentno1november2002.jpg (GRAPHIC) — 133KB
- atmamendmentno1november2003.jpg (GRAPHIC) — 88KB
- atmamendmentno1november2004.jpg (GRAPHIC) — 305KB
- atmamendmentno1november2005.jpg (GRAPHIC) — 60KB
- 0001628280-24-048830.txt ( ) — 1249KB
- cdxc-20241120.xsd (EX-101.SCH) — 2KB
- cdxc-20241120_lab.xml (EX-101.LAB) — 21KB
- cdxc-20241120_pre.xml (EX-101.PRE) — 12KB
- cdxc-20241120_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On November 20, 2024, ChromaDex Corporation (the "Company") entered into an amendment (the "Amendment") to the At Market Issuance Sales Agreement, dated as of June 12, 2020 (the "Sales Agreement") governing the Company's "at-the-market" equity offering program for its common stock, par value $0.001 per share, in order to (i) revise the list of Sales Agents under the program to include Roth Capital Partners, LLC ("Roth Capital Partners"), (ii) remove B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.) as Sales Agent, (iii) update the provisions regarding notice accordingly, and (iv) make other conforming changes. As a result of the Amendment, Raymond James & Associates, Inc. and Roth Capital Partners will continue as the Sales Agents pursuant to the Sales Agreement. A copy of the Amendment, dated November 20, 2024, is filed as Exhibit 1.1 to this Current Report on Form 8-K, and the description of the material terms of the Amendment in this Item 1.01 is qualified in its entirety by reference to the Amendment, which is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 1.1 Amendment No. 1, dated November 20, 2024, to the At Market Issuance Sale Agreement, dated June 12, 2020 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHROMADEX CORPORATION Dated: November 21, 2024 By: /s/ Robert Fried Name: Robert Fried Chief Executive Officer